Richmond American Homes Announces Two Community Grand Openings In Northern Virginia

RESTON, Va., Sept. 7, 2017 /PRNewswire/ -- Richmond American Homes of Virginia, Inc., a subsidiary of M.D.C. Holdings, Inc. (NYSE: MDC), is excited to announce the debut of two exceptional new communities in northern Virginia. Twin Lakes Overlook and Mountain Brook Estates are now selling, and model homes will open for tours at both locations later this year.

Just minutes from Old Town Winchester, Twin Lakes Overlook offers seven inspired ranch and two-story floor plans with two to seven bedrooms and approximately 2,000 to 3,700 square feet. Prices at this community, which features a picturesque lake and trails, start from the low $300s. Prospective buyers can look forward to touring the Amherst and Decker model homes within the next few months.

Mountain Brook Estates boasts six exciting floor plans, including three from the builder's sought-after Seasons™ Collection, designed to put homeownership within reach for a wide range of buyers. This notable new neighborhood – within walking distance of downtown Culpeper – offers two to six bedrooms and approximately 1,985 to 2,785 square feet, from the mid $200s. Residents will appreciate a community playground and easy access to popular commuter routes. The Citrine model will open for tours later this year.

Call 540.548.4435 or visit RichmondAmerican.com for more information.

About M.D.C. Holdings, Inc.

Since 1977, MDC's homebuilding subsidiary companies, which operate under the name Richmond American Homes, have built and financed the American dream for more than 190,000 homebuyers. MDC's commitment to customer satisfaction, quality and value is reflected in the homes its subsidiaries build. MDC is one of the largest homebuilders in the United States. Its subsidiaries have homebuilding operations across the country, including the metropolitan areas of Denver, Northern Colorado,  Colorado Springs, Salt Lake City, Las Vegas, Phoenix, Tucson, Riverside-San Bernardino, Los Angeles, San Diego, Orange County, San Francisco Bay Area, Sacramento, Washington D.C., Baltimore, Northern Virginia, Orlando, Jacksonville, South Florida and Seattle. MDC's subsidiaries also provide mortgage financing, insurance and title services, primarily for Richmond American homebuyers, through HomeAmerican Mortgage Corporation, American Home Insurance Agency, Inc. and American Home Title and Escrow Company, respectively. M.D.C. Holdings, Inc. is traded on the New York Stock Exchange under the symbol "MDC." For more information, visit MDCHoldings.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/richmond-american-homes-announces-two-community-grand-openings-in-northern-virginia-300515902.html

SOURCE M.D.C. Holdings, Inc.

Engelstad Family Foundation Pledges $10 million Gift to Advance Roseman University’s College of Medicine

- Donation leads $66 million campaign -

LAS VEGAS, Sept. 7, 2017 /PRNewswire-USNewswire/ -- Roseman University College of Medicine today announced a $10 million pledge gift from the Engelstad Family Foundation to help advance the opening of Nevada's first private, non-profit, MD-granting medical school in Summerlin.

The donation, the largest in Roseman University's history, kicks off "Breakthrough in Medicine!," a $66 million fundraising campaign that will ensure the College of Medicine fulfills its mission to improve the health of the communities in southern Nevada by providing funding to hire the critical faculty and staff needed as it continues through the rigorous accreditation process. The College of Medicine is currently an applicant with the Liaison Committee on Medical Education (LCME) and has a goal to achieve accreditation to enroll its first class of 64 students in the summer of 2019.

"In addition to the institutional resources provided by Roseman University, this pledged gift is a significant step in our effort to raise the $66 million needed to establish a premier private, MD-granting medical school that will help Nevada communities overcome the chronic shortage of physicians and improve healthcare outcomes," said Mark A. Penn, MD, MBA, founding dean of the Roseman University College of Medicine.

"As a non-profit, private medical school, built without the support of state funding, we are extremely grateful for the generosity and support of the Engelstad Family Foundation and the many business and community members who have also embraced our mission and vision, and supported the College with philanthropic gifts. Additional support is needed as we work towards our goal of raising $66 million," added Penn.

In making the donation, the Engelstad Family Foundation stated, "The Engelstad Family Foundation applauds the work of Roseman University College of Medicine and their endeavor to raise $66 million to ultimately improve healthcare in Southern Nevada through their 'Breakthrough in Medicine' campaign for Roseman University's medical school in Summerlin – the first of its kind in Nevada."

According to Roseman University President Renee Coffman, PhD, in making this landmark pledge gift, the Engelstad Family Foundation will help transform the healthcare landscape in Nevada. "Roseman University and the Engelstad Family Foundation have a shared vision for our state's future – a Nevada where every resident has access to high-quality primary care and medical specialties," said Coffman.

About the Roseman University College of Medicine
Roseman University began building the foundation for its MD-granting College of Medicine in 2010 through the establishment of medical research programs. On December 13, 2013, the Board of Trustees of Roseman University unanimously approved the university's plan to develop an allopathic medical school in Southern Nevada. The College of Medicine is housed at Roseman University's Summerlin campus.

About Roseman University of Health Sciences
Founded in Henderson, Nevada in 1999, Roseman University of Health Sciences is a non-profit, private institution of higher learning training the next generation of undergraduate and graduate level health care professionals that serve, collaborate and set new standards in their communities and within their professions. With campuses in Henderson, Summerlin in Nevada and South Jordan, Utah, the University is comprised of the College of Dental Medicine, offering an Advanced Education in Orthodontics and Dentofacial Orthopedics/MBA residency, Advance Education in General Dentistry residency and Doctor of Dental Medicine program; College of Pharmacy, offering a Doctor of Pharmacy and Professional Continuing Education; College of Nursing, offering a Bachelor of Science in Nursing, Accelerated Bachelor of Science in Nursing and RN to BSN; and an healthcare focused MBA program. Roseman University of Health Sciences will also offer a Doctor of Medicine through its College of Medicine once it becomes accredited. More than 4,000 Roseman graduates are caring for patients, conducting research, and engaged in public health and policy in Nevada, Utah and across the country. Roseman University is regionally accredited by the Northwest Commission on Colleges and Universities.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/engelstad-family-foundation-pledges-10-million-gift-to-advance-roseman-universitys-college-of-medicine-300515862.html

SOURCE Roseman University of Health Sciences

Tilted Kilt Kicks Off The Football Season with New Menu Highlighting Fresh Ingredients

National Sports Pub Adds Mouthwatering Dishes to Redesigned Menu

TEMPE, Ariz., Sept. 7, 2017 /PRNewswire/ -- Tilted Kilt Pub & Eatery®, a sports Pub where "A Cold Beer Never Looked So Good®" has unveiled its newest menu just in time for the football season.

Paying homage to the old public houses of America, England, Scotland, and Ireland by combining classic Celtic décor, sexy servers, and traditional pub fare under one roof, the popular Arizona-based franchise is providing guests with a menu revamp focusing on fresh ingredients and co-branded dishes. These offerings will available in all pubs across the nation by September 12, 2017. Some notable items include:

  • Pub Pretzel: Fresh-baked soft pretzel, brushed with melted butter and dusted with pretzel salt. Served with Fat Tire® Ale Beer Cheese Sauce, honey mustard sauce and pepper jack cheese sauce.
  • Chicago Combo: Juicy Italian beef and mild Italian sausage with roasted peppers and onions on a hoagie roll. Add Giardiniera for an extra kick.
  • Monte Cristo: A triple-decker sandwich with ham, turkey, American and Swiss cheeses, dipped in beer batter and fried.
  • Loaded Tilted Tots: Golden tater tots smothered in Fat Tire Ale Beer cheese sauce, bacon, green onions, and sour cream.
  • Citrus Crusted Codd: Three cod filets pan-seared in a house made lemon citrus sauce, served over a bed of rice pilaf with assorted stir-fried veggies.

The new options put an added focus on fresh ingredients and presentation. Tilted Kilt is aiming to offer guests a wide variety of food and drink options from comfort food and sharables to wholesome healthy offerings and a smaller portion selection. In addition to the updated items, Tilted Kilt pubs are co-branding with key vendors like Guinness®, Samuel Adams®, Fat Tire®, Pretzel Baron and Rosina for infused flavors.

"Our new menu was designed to keep up with popular demand for unique, high-quality, and craveable appetizers, sharables, and entrees," stated Ron Lynch, president of Tilted Kilt. "Everyone is looking for delicious food that is also 'picture perfect', which we have achieved through our offerings. We are excited about the positive reactions these dishes receive from Tilted Kilt guests."

Tilted Kilt has more than 70 locations across the United States and Canada and boasts a wide array of sports and traditional pub food and drinks all under one roof. Combined with pool tables, large TVs, and additional amenities, Tilted Kilt is the best place to watch sports and hang out with friends. Humorous and slightly bawdy limericks are seen throughout the pub, creating an atmosphere that is fun and entertaining.

For more information about Tilted Kilt or to find your nearest location, visit tiltedkilt.com.

About Tilted Kilt
Tilted Kilt Pub and Eatery, known as "The Best Looking Sports Pub You've Ever Seen," has 70+ units in operation throughout the U.S. and Canada, with additional 20 pubs in various stages of development. Tilted Kilt is uniquely different than other sports bars because of its fun pub experience. The Pubs feature dozens of large, HDTVs and big screens to deliver a premium sports viewing experience. Every Pub has 30+ draught and bottled beers along with excellent tasting, high quality menu items served to you by the World Famous Kilt Girls ®. The Tilted Kilt Girls and Guys are inviting and represent the comfortable atmosphere while simultaneously demonstrating a high level of service in the industry. The brand's slogan "A Cold Beer Never Looked So Good ®" personifies the Fun, Food, Spirits and Sports that the Tilted Kilt is well-known for bringing to pub guests in both the United States and Canada.

MEDIA CONTACT: Kathryn Frakes, Fishman Public Relations, 847-945-1300, kfrakes@fishmanpr.com

View original content with multimedia:http://www.prnewswire.com/news-releases/tilted-kilt-kicks-off-the-football-season-with-new-menu-highlighting-fresh-ingredients-300515986.html

SOURCE Tilted Kilt Pub & Eatery

NSI Technologies, a Premier Oilfield Laboratories Company, is Slated to Unveil StimPlan(TM) Version 8.0 at the 2017 SPE-ATCE in San Antonio

HOUSTON, Sept. 7, 2017 /PRNewswire/ -- NSI Technologies, a Premier Oilfield Laboratories Company, is proud to announce the launch of Version 8 of StimPlan™ Hydraulic Fracturing Software at the 2017 Society of Petroleum Engineers Annual Technology Conference and Exposition in San Antonio this October.  The highly-anticipated version features a complete program rewrite helping to provide additional stability and improved processing time as well as a completely new user interface designed to provide a more intuitive workflow.  

NSI Technologies President and StimPlan™ creator Dr. Michael Smith said, "We are very excited to begin our roll out of StimPlan™ version 8. This version builds on our established framework while providing additional features aimed at the modern fracturing engineer working in an unconventional environment."

Just prior to the announcement of Version 8, NSI Technologies added the ability to simulate multiple, parallel fractures with the ability to determine how the mechanical interference (stress shadowing) between fractures is calculated. Additional StimPlan™ features include:

  1. Expanded "batch" capabilities to better allow for sensitivity studies
  2. New input allowing the Geologic Layering to be shifted (creating a new Geologic Model) for each stage of a horizontal well
  3. Discrete natural fracture network inputs can now be transferred to the reservoir simulation for a rigorous simulation of a natural fractured reservoir
  4. Direct inputs have been added for performing stage-to-stage interference simulations

NSI and Premier will be demonstrating version 8 at booth 2344 at the 2017 SPE-ATCE event in San Antonio. Visit www.nsitech.com for more about StimPlan™ and a complete list of demonstration times.

About StimPlan™: For more than thirty years StimPlan™ has been an industry leading complete and integrated software solution for hydraulic fracture design, analysis, and optimization. With a comprehensive integrated toolkit and the industry's most rigorous geometry models, StimPlan™ helps operators worldwide maximize their well performance while lowering expenditure and reducing their environmental footprint, however complex their reservoir or fracture treatment design.

About Premier Oilfield Laboratories: Premier brings together a multidisciplinary team of experts who utilize breakthrough technologies and progressive approaches to help our clients understand how to better design exploration and exploitation strategies, optimize production, and mitigate risk. Please visit Premier Oilfield Laboratories at www.premieroilfieldlabs.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/nsi-technologies-a-premier-oilfield-laboratories-company-is-slated-to-unveil-stimplan-version-80-at-the-2017-spe-atce-in-san-antonio-300515966.html

SOURCE Premier Oilfield Laboratories, LLC

PREIT Completes Anchor Improvement Program at Viewmont Mall with Opening of HomeGoods, DICK’S Sporting Goods and Field & Stream

Multi-year remerchandising efforts at dominant mall yields diversified tenant mix aligned with the new age of retailing

PHILADELPHIA, Sept. 7, 2017 /PRNewswire/ -- PREIT (NYSE: PEI) announces the opening of three new retailers at Viewmont Mall in Scranton, PA, where the Company recast its anchor mix to further diversify and enhance the shopper experience. DICK'S Sporting Goods, Field & Stream and HomeGoods have recently opened within the space formerly occupied by Sears and proactively recaptured by PREIT. Within 14 months of Sears' closing, the opening of these popular new retailers demonstrates PREIT's proficiency in identifying and securing quality and high performing replacement anchors. 

As PREIT remerchandises its properties with in-demand retailers, the Company continues to add value to its repositioned portfolio. Over the past few years, Viewmont Mall has been a key focus of PREIT's portfolio-wide remerchandising efforts, including the addition of national tenants Ulta, Buffalo Wild Wings, Forever 21 and Yankee Candle accompanied by new prototype stores for several key tenants. These efforts have organically driven a $57, or 16% increase, in sales per square foot since December 31, 2013 and set the stage for reshaping the recaptured Sears store.

"Viewmont Mall exemplifies the extensive remerchandising and proactive anchor recapture strategy we have employed across our portfolio responding to consumer demands for more exciting shopping venues," said PREIT CEO Joseph F. Coradino. "We continue to enhance our portfolio ahead of the dynamic retail landscape with this marking the first of four anchors opening this year, driving traffic, sales and NOI."

DICK'S Sporting Goods and Field & Stream occupy 90,000 square feet in one of only a few dual store concept stores in the country. The retailers will serve the needs of Northeastern PA shoppers traveling through the area on their way to the nearby Pocono resorts, a top destination for sporting, hunting and fishing enthusiasts. HomeGoods, a top tier retailer, which offers an ever-changing selection of unique home fashions at an affordable price, occupies 23,000 square feet of space and opened in August.

About PREIT
PREIT (NYSE:PEI) is a publicly traded real estate investment trust that owns and manages quality properties in compelling markets. PREIT's robust portfolio of carefully curated retail and lifestyle offerings mixed with destination dining and entertainment experiences are located primarily in the densely-populated eastern U.S. with concentrations in the mid-Atlantic's top MSAs. Since 2012, the company has driven a transformation guided by an emphasis on portfolio quality and balance sheet strength driven by disciplined capital expenditures. Additional information is available at www.preit.com or on Twitter or LinkedIn.

CONTACT:
Heather Crowell
SVP, Corporate Communications and Investor Relations
(215) 454-1241
heather.crowell@preit.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/preit-completes-anchor-improvement-program-at-viewmont-mall-with-opening-of-homegoods-dicks-sporting-goods-and-field--stream-300515903.html

SOURCE PREIT

Micro Interventional Devices, Inc.(TM) Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA(TM) Technology

NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc.™ (MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology.  The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient's tricuspid regurgitation from severe/moderate to trace. The patient was the fourth to be enrolled in MID's STTAR Trial (Study of Transcatheter Tricuspid Annular Repair).  All four patients have been successfully treated with 100% procedural success and no adverse events reported.

"This patient represents an evolution in the clinical use of MIA.  This is the first time MIA was utilized to perform a bicuspidization of the patient's tricuspid valve," stated Michael Whitman, MID's President and CEO.  "The shift to a bicuspidization approach on our fourth patient provided a superior outcome and was easier to perform than our initial three patients.  This is not surprising as clinical experience is applied to greater procedural affect.  The acute results for this patient appear comparable to open bicuspidization procedures." 

The fourth patient enrolled in the STTAR study on Wednesday, August 23rd was treated with a second generation MIA implant that allows for greater annular reduction with fewer implants. The procedure was performed by Professor Kestutis Rucinskas, MD, Chief of Cardiac Surgery, and Professor Audrius Aidietis, MD, Chief of Cardiology and Angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania.  As with the other STTAR cases, there were no intraoperative complications or adverse events observed or reported. 

By using a bicuspidization approach with the second-generation technology, the annular reduction may prove to be easier, faster and more durable.  The tricuspid repair portion of the procedure was completed in 15 minutes.

"This fourth clinical case marks a significant milestone for the company as the MIA technology continues to prove effective in open surgery," stated Michael Whitman, President and CEO of MID.  "With the confirmation of the implant's effectiveness, our next step is to convert this technology to a 12F catheter-based delivery system which has been in development for some time.  We expect to perform the first percutaneous bicuspidization with MIA in Q4 of this year."

"The MIA deployment took approximately 15 minutes in open surgery.  Therefore, we expect the percutaneous deployments to take less than thirty minutes," stated Willard Hennemann, PhD, MID's Chief Science Officer.  "MIA percutaneous can be deployed from the atrium via transfemoral access, avoiding subvalvular structures, and improving the ease of use.  This may open the door for treatment of the approximately 2.3 million patients worldwide who are not currently being treated for mitral and tricuspid regurgitation, as they are unable to tolerate open surgery.  This first in human result indicates that MIA will be a viable treatment for functional tricuspid disease."

MIA utilizes proprietary compliant PolyCorTM anchors, the world's first low mass polymeric implant designed to comply with normal physiological valvular function.  The MIA implant is engineered to plicate and comply with cardiac tissue once deployed.  

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270
info@microinterventional.com
www.microinterventional.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/micro-interventional-devices-inc-completes-first-clinical-tricuspid-bicuspidization-procedure-utilizing-mia-technology-300515920.html

SOURCE Micro Interventional Devices, Inc.

Micro Interventional Devices, Inc.(TM) Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA(TM) Technology

NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc.™ (MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology.  The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient's tricuspid regurgitation from severe/moderate to trace. The patient was the fourth to be enrolled in MID's STTAR Trial (Study of Transcatheter Tricuspid Annular Repair).  All four patients have been successfully treated with 100% procedural success and no adverse events reported.

"This patient represents an evolution in the clinical use of MIA.  This is the first time MIA was utilized to perform a bicuspidization of the patient's tricuspid valve," stated Michael Whitman, MID's President and CEO.  "The shift to a bicuspidization approach on our fourth patient provided a superior outcome and was easier to perform than our initial three patients.  This is not surprising as clinical experience is applied to greater procedural affect.  The acute results for this patient appear comparable to open bicuspidization procedures." 

The fourth patient enrolled in the STTAR study on Wednesday, August 23rd was treated with a second generation MIA implant that allows for greater annular reduction with fewer implants. The procedure was performed by Professor Kestutis Rucinskas, MD, Chief of Cardiac Surgery, and Professor Audrius Aidietis, MD, Chief of Cardiology and Angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania.  As with the other STTAR cases, there were no intraoperative complications or adverse events observed or reported. 

By using a bicuspidization approach with the second-generation technology, the annular reduction may prove to be easier, faster and more durable.  The tricuspid repair portion of the procedure was completed in 15 minutes.

"This fourth clinical case marks a significant milestone for the company as the MIA technology continues to prove effective in open surgery," stated Michael Whitman, President and CEO of MID.  "With the confirmation of the implant's effectiveness, our next step is to convert this technology to a 12F catheter-based delivery system which has been in development for some time.  We expect to perform the first percutaneous bicuspidization with MIA in Q4 of this year."

"The MIA deployment took approximately 15 minutes in open surgery.  Therefore, we expect the percutaneous deployments to take less than thirty minutes," stated Willard Hennemann, PhD, MID's Chief Science Officer.  "MIA percutaneous can be deployed from the atrium via transfemoral access, avoiding subvalvular structures, and improving the ease of use.  This may open the door for treatment of the approximately 2.3 million patients worldwide who are not currently being treated for mitral and tricuspid regurgitation, as they are unable to tolerate open surgery.  This first in human result indicates that MIA will be a viable treatment for functional tricuspid disease."

MIA utilizes proprietary compliant PolyCorTM anchors, the world's first low mass polymeric implant designed to comply with normal physiological valvular function.  The MIA implant is engineered to plicate and comply with cardiac tissue once deployed.  

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270
info@microinterventional.com
www.microinterventional.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/micro-interventional-devices-inc-completes-first-clinical-tricuspid-bicuspidization-procedure-utilizing-mia-technology-300515920.html

SOURCE Micro Interventional Devices, Inc.

Micro Interventional Devices, Inc.(TM) Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA(TM) Technology

NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc.™ (MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology.  The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient's tricuspid regurgitation from severe/moderate to trace. The patient was the fourth to be enrolled in MID's STTAR Trial (Study of Transcatheter Tricuspid Annular Repair).  All four patients have been successfully treated with 100% procedural success and no adverse events reported.

"This patient represents an evolution in the clinical use of MIA.  This is the first time MIA was utilized to perform a bicuspidization of the patient's tricuspid valve," stated Michael Whitman, MID's President and CEO.  "The shift to a bicuspidization approach on our fourth patient provided a superior outcome and was easier to perform than our initial three patients.  This is not surprising as clinical experience is applied to greater procedural affect.  The acute results for this patient appear comparable to open bicuspidization procedures." 

The fourth patient enrolled in the STTAR study on Wednesday, August 23rd was treated with a second generation MIA implant that allows for greater annular reduction with fewer implants. The procedure was performed by Professor Kestutis Rucinskas, MD, Chief of Cardiac Surgery, and Professor Audrius Aidietis, MD, Chief of Cardiology and Angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania.  As with the other STTAR cases, there were no intraoperative complications or adverse events observed or reported. 

By using a bicuspidization approach with the second-generation technology, the annular reduction may prove to be easier, faster and more durable.  The tricuspid repair portion of the procedure was completed in 15 minutes.

"This fourth clinical case marks a significant milestone for the company as the MIA technology continues to prove effective in open surgery," stated Michael Whitman, President and CEO of MID.  "With the confirmation of the implant's effectiveness, our next step is to convert this technology to a 12F catheter-based delivery system which has been in development for some time.  We expect to perform the first percutaneous bicuspidization with MIA in Q4 of this year."

"The MIA deployment took approximately 15 minutes in open surgery.  Therefore, we expect the percutaneous deployments to take less than thirty minutes," stated Willard Hennemann, PhD, MID's Chief Science Officer.  "MIA percutaneous can be deployed from the atrium via transfemoral access, avoiding subvalvular structures, and improving the ease of use.  This may open the door for treatment of the approximately 2.3 million patients worldwide who are not currently being treated for mitral and tricuspid regurgitation, as they are unable to tolerate open surgery.  This first in human result indicates that MIA will be a viable treatment for functional tricuspid disease."

MIA utilizes proprietary compliant PolyCorTM anchors, the world's first low mass polymeric implant designed to comply with normal physiological valvular function.  The MIA implant is engineered to plicate and comply with cardiac tissue once deployed.  

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270
info@microinterventional.com
www.microinterventional.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/micro-interventional-devices-inc-completes-first-clinical-tricuspid-bicuspidization-procedure-utilizing-mia-technology-300515920.html

SOURCE Micro Interventional Devices, Inc.

Micro Interventional Devices, Inc.(TM) Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA(TM) Technology

NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc.™ (MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology.  The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient's tricuspid regurgitation from severe/moderate to trace. The patient was the fourth to be enrolled in MID's STTAR Trial (Study of Transcatheter Tricuspid Annular Repair).  All four patients have been successfully treated with 100% procedural success and no adverse events reported.

"This patient represents an evolution in the clinical use of MIA.  This is the first time MIA was utilized to perform a bicuspidization of the patient's tricuspid valve," stated Michael Whitman, MID's President and CEO.  "The shift to a bicuspidization approach on our fourth patient provided a superior outcome and was easier to perform than our initial three patients.  This is not surprising as clinical experience is applied to greater procedural affect.  The acute results for this patient appear comparable to open bicuspidization procedures." 

The fourth patient enrolled in the STTAR study on Wednesday, August 23rd was treated with a second generation MIA implant that allows for greater annular reduction with fewer implants. The procedure was performed by Professor Kestutis Rucinskas, MD, Chief of Cardiac Surgery, and Professor Audrius Aidietis, MD, Chief of Cardiology and Angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania.  As with the other STTAR cases, there were no intraoperative complications or adverse events observed or reported. 

By using a bicuspidization approach with the second-generation technology, the annular reduction may prove to be easier, faster and more durable.  The tricuspid repair portion of the procedure was completed in 15 minutes.

"This fourth clinical case marks a significant milestone for the company as the MIA technology continues to prove effective in open surgery," stated Michael Whitman, President and CEO of MID.  "With the confirmation of the implant's effectiveness, our next step is to convert this technology to a 12F catheter-based delivery system which has been in development for some time.  We expect to perform the first percutaneous bicuspidization with MIA in Q4 of this year."

"The MIA deployment took approximately 15 minutes in open surgery.  Therefore, we expect the percutaneous deployments to take less than thirty minutes," stated Willard Hennemann, PhD, MID's Chief Science Officer.  "MIA percutaneous can be deployed from the atrium via transfemoral access, avoiding subvalvular structures, and improving the ease of use.  This may open the door for treatment of the approximately 2.3 million patients worldwide who are not currently being treated for mitral and tricuspid regurgitation, as they are unable to tolerate open surgery.  This first in human result indicates that MIA will be a viable treatment for functional tricuspid disease."

MIA utilizes proprietary compliant PolyCorTM anchors, the world's first low mass polymeric implant designed to comply with normal physiological valvular function.  The MIA implant is engineered to plicate and comply with cardiac tissue once deployed.  

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270
info@microinterventional.com
www.microinterventional.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/micro-interventional-devices-inc-completes-first-clinical-tricuspid-bicuspidization-procedure-utilizing-mia-technology-300515920.html

SOURCE Micro Interventional Devices, Inc.

Nordic Energy Launches Alpine Energy Systems’ Sales Commission Module

OAK BROOK, Ill., Sept. 7, 2017 /PRNewswire/ -- Nordic Energy is pleased to announce its successful implementation of Alpine's Commission Module. The module delivers a series of benefits to a robust, fully integrated system that offers complete flexibility for commission calculations and reconciliations. By incorporating these new features, Nordic has expanded its suite of Alpine products gaining more complete capabilities to run its sales and operations teams more efficiently.

Alpine's Commission Module is fully capable and allows retailers to apply a variety of unique commission structures to individual organizations such as one-time payments, residual plans, pre-payments, claw-backs, all with the option of thorough reconciliation. The simplified data gathering process reflects actual versus estimated commissions. The calculations and reporting incorporated into this module save countless man hours giving suppliers the ability to expand their business quickly without extensive team expenditures.

"Nordic is excited about the efficiencies brought by Alpine's commission system," explains Jim Deering, President and CEO of Nordic Energy. "We have reduced staffing by over 40% in this area and are providing accurate and timely commission payments to our valued agent network. Alpine was able to handle our complex product structures and delivered our project on time and within budget."

"As an established and trusted energy supplier with operations in multiple territories, Alpine appreciates Nordic Energy's decision to expand into complementary Alpine modules," said Michael Wood, Principal of Alpine.  "The Commission Module can be bolted onto Alpine's core offering or run by our customers in a stand alone, commission only instance. This solution furthers Alpine's mission of automating complex business practices and data management." 

Alpine Energy Systems, LLC (www.alpineenergysystems.com) offers a robust suite of sales software to the retail energy industry. From managing sales channels including real-time custom pricing to processing complex commissions to running risk management reporting, Alpine Energy Systems' market-leading tools allow suppliers to focus on growth, profits and other critical business aspects. Since its inception in 2010, Alpine Energy Systems' software has proven to drastically improve retail energy providers' existing sales processes while integrating with a number of industry-recognized EDI/billing vendors and platforms.

Nordic Energy Services, LLC (www.nordicenergy-us.com) is an independently owned, Chicago-based, Alternative Retail Electric Supplier (ARES) and Alternative Gas Supplier (AGS). Nordic Energy supplies natural gas and/or electricity with related services to commercial customers, municipalities and residential customers in Illinois, Indiana, Michigan, Massachusetts, Ohio, Pennsylvania, Ohio, Maryland and New York. Working toward its mission of being a fully integrated energy provider, Nordic also produces oil and natural gas commodities. For their commercial customers, Nordic offers customized risk management and hedging solutions, energy scheduling, and bill audit services.

For further information please contact:
Alpine Energy Systems, LLC: 
Kristie Eickhoff
+1.630.320.9128
keickhoff@alpineenergysystems.com

 

View original content:http://www.prnewswire.com/news-releases/nordic-energy-launches-alpine-energy-systems-sales-commission-module-300515889.html

SOURCE Nordic Energy Services, LLC